Financial performance of innovation in the life sciences economy—Tracking the IPO Class through twists and turns

4:00 PM - 4:45 PM (EDT), Tuesday, June 15, 2021
Search General Info
Search Education
Search Partnering Companies

The IPO Class has grown over the last 8 years and continued through a COVID-19 inflection. This session tracks the financial performance and offers insights about the IPO Class, the most innovative group of the public life sciences sector.
• Have Digital Health companies joined this class?
• What impacts have SPACs had on the opportunities for innovative companies?
• What has been the impact of COVID-19 and what does the peer group look like?
• Lessons learned about the value of new and innovative therapeutics
• Debating and discussing:
• How has the signing of deals evolved with market capitalization?
• Are we seeing re-positioning given the need for COVID-19 diagnostics, therapeutics and vaccines?
• What is the likely impact on the future of the industry of this set of innovative companies?

Moderator
photo
CEO
bdlBiologx
Speakers
photo
Partner
Jones Day
photo
Managing Director
Bioscience Advisors, Inc.
photo
CEO
bdlBiologx
photo
Vice President, Corporate Development
Harpoon Therapeutics
photo
Partner
Acilon Consulting